Cerecor (CERC) – StreetInsider.com Reports
-
Pre-Open Stock Movers 07/27: (OGEN) (OBSV) (FFIV) Higher; (BTBT) (MINM) (UPS) Lower (more...)
-
After-Hours Stock Movers 07/26: (CERC) (UHS) (FFIV) Higher; (BTBT) (MINM) (TDUP) Lower (more...)
-
Cerecor (CERC) Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
-
Cerecor (CERC) Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
-
Cantor Fitzgerald Starts Cerecor (CERC) at Overweight
-
Cerecor (CERC) PT Lowered to $7 at Oppenheimer
-
Pre-Open Stock Movers 05/11: (FOE) (CERC) (UFS) Higher; (JMIA) (RXT) (SPCE) Lower (more...)
-
Cerecor (CERC) Announces FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
-
Cerecor (CERC) Reports First Patient Dosing in Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for Treatment of Adult Onset Still’s Disease
-
Pre-Open Stock Movers 04/21: (OCGN) (WBT) (ISRG) Higher; (DGLY) (NFLX) (ROKU) Lower (more...)
-
Maxim Group Upgrades Cerecor (CERC) to Buy
-
UPDATE: Jefferies Starts Cerecor (CERC) at Buy
-
Cerecor (CERC) Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
-
Cerecor (CERC) Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
-
Cerecor (CERC) Appoints Schond L. Greenway as Chief Financial Officer
-
Cerecor (CERC) Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
-
Cerecor (CERC) Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
-
Pre-Open Stock Movers 01/08: (VIH) (GSAT) (CMRX) Higher; (SRPT) (SLDB) (NLTX) Lower (more...)
-
Cerecor (CERC) Prices $36.4M Common Share Offering and Pre-Funded Warrants
-
After-Hours Stock Movers 01/07: (MRUS) (MICT) (WDFC) Higher; (SRPT) (SLDB) (BNGO) Lower (more...)
-
Cerecor (CERC) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Cerecor (CERC) Reports Successful Proof of Concept Data for CERC-002 in Patients Hospitalized with COVID-19 ARDS
-
Cerecor (CERC) Announces FDA Acceptance of IND for CERC-007 for Treatment of Still's Disease
-
Cerecor (CERC) Reports First Patient Dosed in Phase 1b Clinical Trial of CERC-007
-
Cerecor (CERC) Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma
-
Cerecor (CERC) PT Lowered to $9 at Oppenheimer
-
Cerecor (CERC) Announces Gilla Kaplan, Ph.D. to Board
-
Cerecor (CERC) Reports Continuation of Phase 1b Clinical Trial of CERC-002 for Treatment of Severe Pediatric Onset Crohn’s Disease
-
Cerecor (CERC) Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS
-
Cerecor (CERC) Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
-
Cerecor (CERC) Announces FDA Granted Orphan Drug Designation for CERC-006 in Lymphatic Malformations
-
Pre-Open Stock Movers 06/09: (NKLA) (LOVE) (M) Higher; (SLNO) (CHK) (CERC) Lower (more...)
-
Cerecor (CERC) Prices 13.2M Share Common Offering at $2.50/Sh
-
After-Hours Stock Movers 6/8: (M) (CFRX) (SMG) HIGHER; (SLNO) (CHK) (CERC) LOWER (more...)
-
Cerecor (CERC) Announces Proposed Public Offering of Common Stock
-
Cerecor (CERC) Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS
-
Oppenheimer Reiterates Outperform Rating on Cerecor (CERC) on Potential Role in Severe COVID-19
-
Cerecor (CERC), Myriad Genetics (MYGN) Report Levels of LIGHT, a Novel Cytokine, were Highly Correlated with Disease Severity & Mortality in COVID-19 ARDS Biomarker Study
-
Cerecor (CERC) Appoints Dr. Sol J. Barer to Board Chairman; Adds Dr. Suzanne Bruhn and Mr. Joseph Miller to Board
-
Cerecor (CERC) Announces Exploration of Role of Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to ARDS
-
Maxim Group Downgrades Cerecor (CERC) to Hold
-
Oppenheimer Starts Cerecor (CERC) at Outperform
-
Cerecor (CERC) to Acquire Aevi Genomic Medicine (GNMX) in All-Stock Transaction
-
Cerecor (CERC) PT Raised to $12 at H.C. Wainwright
-
Cerecor (CERC) Reports In-Line Q3 EPS
-
Cerecor (CERC) Reports Clinical Updates on CERC-301 and CERC-802
-
Aytu BioScience (AYTU) Confirms Agreement to Acquire $12.4 Million Prescription Product Portfolio from Cerecor (CERC)
-
Cerecor (CERC) Reports Sale of Pediatric Portfolio to AYTU BioScience
-
Cerecor (CERC) to Sell Pediatric Portfolio to AYTU BioScience in Deal Valued in Excess of $32M
-
Cerecor (CERC) Granted Fast Track Designation from FDA for CERC-802 for Treatment of Mannose-Phosphate Isomerase Deficiency
Back to CERC Stock Lookup